Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Purinergic Signalling is Scopus-indexed (Q3, CiteScore 5.2), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Springer Science and Business Media B.V..
Checked against the index lists dated .
ISSN 1573-9538Verify ISSN ↗1573-9546Verify ISSN ↗
Publisher: Springer Science and Business Media B.V.
Cost to publish: About US$4,690 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Molecular Biology | 219 / 414 | 47th | Q3 |
| Cellular and Molecular Neuroscience | 56 / 102 | 45th | Q3 |
| Cell Biology | 169 / 289 | 41st | Q3 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2004–present, best quartile Q3, CiteScore 5.2.
Purinergic Signalling is Q3 in Molecular Biology (rank 219 of 414), Q3 in Cellular and Molecular Neuroscience (rank 56 of 102) and Q3 in Cell Biology (rank 169 of 289), by CiteScore 2025.
Purinergic Signalling is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 5.2, which places it in quartile Q3 at the 47th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.862, quartile Q2, with an H-index of 73.
The publisher lists an article processing charge of about US$4,690 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Purinergic Signalling is published by Springer Science and Business Media B.V. Its print ISSN is 1573-9538 and its online ISSN is 1573-9546.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Purinergic Signalling has an h-index of 79 and a 2-year mean of 2.59 citations per paper (OpenAlex). Its Scopus CiteScore is 5.2, quartile Q3. On 2-year citations it ranks #226 of 411 Scopus journals in Molecular Biology.
Purinergic Signalling published 46 papers in 2025; its busiest recent year was 2022 with 84. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2025–2026), authors are most often from China (20.4%), Brazil (19.6%) and Italy (8.9%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 4 retracted papers are recorded (3.2 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.